Abstract
In the current pandemic finding an effective drug to prevent or treat the infection is the highest priority. A rapid and safe approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 PLpro promotes viral replication and modulates the host immune system, resulting in inhibition of the host antiviral innate immune response, and therefore is an attractive drug target. In this study, we used a combined in silico virtual screening for candidates for SARS-CoV-2 PLpro protease inhibitors. We used the Informational spectrum method applied for Small Molecules for searching the Drugbank database followed by molecular docking. After in silico screening of drug space, we identified 44 drugs as potential SARS-CoV-2 PLpro inhibitors that we propose for further experimental testing.
Supplementary materials
Title
Figure 1
Description
ISM spectrum of SARS-CoV-2 Papain like protease
Actions
Title
Figure 2
Description
Crystal structure of PLpro, with marked catalytic triad (PDBID 6WUU). Marked regions correspond F(0.383) 248-312– blue, and F(0.279) 60-124 – green. The bound compound is the co-crystalized covalent peptide inhibitor VIR250.
Actions
Title
Figure 3
Description
Epicriptine in the PLpro inhibitor binding site. Green lines: hydrogen bonds; orange: electrostatic interactions; purple: alkyl- π interactions, magenta: π-π interactions
Actions
Title
Figure 4
Description
Metergoline in the PLPro inhibitor binding site. Green lines: hydrogen bonds; orange: electrostatic interactions; pur-ple: alkyl- π interactions, magenta: π-π interactions
Actions
Title
Figure 5
Description
Co crystalized ligand GRL 0617 in the PLpro allosteric site. Green lines: hydrogen bonds; purple: al-kyl-π/hydrophobic interactions.
Actions